Roche AG, of Basel, Switzerland, said it entered an agreement with Qiagen NV, of Venlo, the Netherlands, that includes a provision of nonexclusive licenses to recently granted Roche patents pertaining to the detection of mutations in the EGFR pathway, including in the KRAS gene.